Takeda Pharmaceutical Company Limited

4502

JP3463000004

Pharmaceuticals

Delayed Japan Exchange Other stock markets 07:00:00 17/07/2024 BST			5-day change	1st Jan Change
4,309 ^JPY	+1.63%		+1.39%	+6.29%

07-17	Asian Equities Traded in the US as American Depositary Receipts Tumble in Wednesday Trading	MT
07-17	Zydus Lifesciences Signs Licensing Pact to Market Vonoprazan in India	MT

Takeda Pharmaceutical Company Limited Launches Treatment for Ethylene Glycol and Methanol Poisonings in Japan

January 29, 2015 at 09:15 am

Takeda Pharmaceutical Company Limited has announced the availability of Fomepizole Intravenous Infusion 1.5g Takeda, or fomepizol, for the treatment of ethylene glycol and methanol poisonings in Japan. Fomepizole, an alcohol dehydrogenase inhibitor, is marketed and distributed by Paladin Labs Inc. in Canada and is the standard treatment for ethylene glycol and methanol poisonings.

Latest news about Takeda Pharmaceutical Company Limited

Asian Equities Traded in the US as American Depositary Receipts Tumble in Wednesday Trading	07-17	MT
Zydus Lifesciences Signs Licensing Pact to Market Vonoprazan in India	07-17	MT
Takeda Issues New Shares, Disposes of Treasury Shares Under Incentive Scheme	07-09	MT
Blackstone selling Japan drugmaker Alinamin to MBK Partners	07-03	RE
Koru Medical Systems' FreedomEdge System Receives Regulatory Approval in Japan	07-02	MT
KORU Medical Systems Receives Regulatory Clearance for FreedomEdge Infusion System in Japan	07-02	CI
Codexis Sells Fabry, Pompe Disease Compounds to Crosswalk Therapeutics	07-01	MT
Corza Medical Inc. completed the acquisition of TachoSil manufacturing operations in Linz, Austria. from Takeda Pharmaceutical Company Limited.	06-30	CI
Transcript : Takeda Pharmaceutical Company Limited - Shareholder/Analyst Call	06-26
US CDC alerts healthcare providers of increase in dengue cases	06-25	RE
Takeda's Cancer Drug Gets European Commission Approval	06-25	MT
Hutchmed China notes Takeda obtains EU approval for Fruzaqla	06-24	AN
Takeda's Organ Transplant Infection Treatment Approved by Japan Regulators	06-24	MT
Hutchmed (China), Takeda Secure EU Approval for Colorectal Cancer Treatment	06-24	MT
Takeda Announces Approval of LIVTENCITY® by the Japanese Ministry of Health, Labour and Welfare	06-24	CI
Japanese Shares End Higher as BoJ Indicates Readiness for Policy Shifts	06-24	MT
Takeda Receives European Commission Approval for Colorectal Cancer Treatment	06-24	MT
Takeda Receives European Commission Approval for FRUZAQLA® (fruquintinib)	06-23	CI
Takeda Presents Late-Breaking Data from Phase 2b Study of Mezagitamab, Demonstrating Potential to Transform Treatment of Primary Immune Thrombocytopenia	06-23	CI
Takeda Secures European Commission's Approval for Colorectal Cancer Drug Fruzaqla	06-21	MT
Takeda Pharmaceutical Gets European Commission Approval for Cancer Treatment	06-21	DJ
Takeda Receives Approval from European Commission for Fruquintinib in Previously Treated Metastatic Colorectal Cancer	06-21	CI
Japanese Stocks End Little Changed After Three-Day Winning Streak on Inflation and Yen Woes	06-21	MT
Takeda gives Sun Pharma, Cipla rights to commercialize gastro drug in India	06-21	RE
Sun Pharma Signs Deal with Japan's Takeda to Commercialize Vonoprazan in India	06-21	MT

Chart Takeda Pharmaceutical Company Limited

Duration

Period

Chart Takeda Pharmaceutical Company Limited

More charts

Company Profile

Takeda Pharmaceutical Company Limited specializes in the development, manufacturing and marketing of pharmaceutical products especially for metabolic and cardiovascular diseases, cancers and central nervous systems troubles. The activity is organized around 2 areas: - sale of drugs and consumer care products; - services. Net sales are distributed geographically as follows: Japan (17.5%), Asia (5%), the United States (49%), Europe and Canada (20.8%), Latin America (3.8%), Russia and CIS (1.8%) and other (2.1%).

Sector

Pharmaceuticals

Calendar

31/07/2024 - Q1 2024 Earnings Release

Related indices

Nikkei 225

More about the company

Income Statement Evolution

More financial data

Ratings for Takeda Pharmaceutical Company Limited

Trading Rating

Investor Rating

ESG Refinitiv

B+

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

4,309 JPY

Average target price

4,730 JPY

Spread / Average Target

+9.77%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
TAKEDA PHARMACEUTICAL COMPANY LIMITED	+6.29%	42.37B
ELI LILLY AND COMPANY	+55.35%	848B
NOVO NORDISK A/S	+31.64%	627B
JOHNSON & JOHNSON	-0.10%	363B
MERCK & CO., INC.	+15.47%	318B
ABBVIE INC.	+13.10%	299B
ASTRAZENECA PLC	+15.51%	243B
NOVARTIS AG	+16.72%	225B
AMGEN INC.	+16.54%	179B
PFIZER, INC.	+4.31%	167B

Other Pharmaceuticals